BioArctic Dividendes et rachats
Dividende contrôle des critères 0/6
BioArctic est une société versant des dividendes avec un rendement actuel de 0.61%.
Informations clés
0.6%
Rendement du dividende
-0.09%
Rendement des rachats
| Rendement total pour l'actionnaire | 0.5% |
| Rendement futur des dividendes | 0% |
| Croissance des dividendes | 4.4% |
| Prochaine date de paiement du dividende | n/a |
| Date ex-dividende | n/a |
| Dividende par action | n/a |
| Ratio de distribution | 83% |
Mises à jour récentes sur les dividendes et les rachats
Recent updates
Mise à jour du récit • Jul 29
BIOA B: Alzheimer’s Outcomes And Aging Biology Partnerships Will Shape Balanced Outlook
Analysts have raised their BioArctic price target from SEK303.80 to SEK316.75, citing updated assumptions on revenue growth, profit margin, and a lower future P/E multiple that they view as more closely aligned with recent Street research on comparable aging-related therapeutics companies. Analyst Commentary Street research on aging related therapeutics is shaping how bullish analysts frame expectations for BioArctic.
Mise à jour du récit • Jun 16
BIOA B: Future Returns Will Depend On Sustained NLRP3 Execution Risk
Analysts have maintained their SEK 240.00 price target on BioArctic, citing materially higher modeled revenue growth of 14.61% and a stronger 23.70% profit margin outlook, partly offset by a lower future P/E assumption of 61.02x. Analyst Commentary Recent research around BioArctic highlights a split view between optimism on the long term opportunity and caution on what is already reflected in the share price.
Mise à jour du récit • Jun 01
BIOA B: Alzheimer’s Access Delays And Nordic Rollout Will Shape Future Returns
Analysts now set their fair value estimate for BioArctic at SEK 363, down slightly from SEK 367. This reflects updated assumptions around revenue growth, profit margins and a lower future P/E multiple.Article d’analyse • May 28
BioArctic's (STO:BIOA B) Soft Earnings Don't Show The Whole Picture
BioArctic AB (publ)'s ( STO:BIOA B ) stock was strong despite it releasing a soft earnings report last week. We think...Article d’analyse • May 24
BioArctic AB (publ) Just Reported A Surprise Profit, And Analysts Lifted Their Estimates
As you might know, BioArctic AB (publ) ( STO:BIOA B ) recently reported its quarterly numbers. Revenues of 66% beat...Mise à jour du récit • May 18
BIOA B: Future Returns Will Depend On High NLRP3 Execution Risk
Analysts kept their SEK 240.00 price target for BioArctic unchanged, with slightly lower discount rate and profit margin assumptions, and a higher future P/E multiple that reflects refined views on the stock's risk profile and earnings power. Analyst Commentary Recent research on BioArctic has centered on how changing assumptions around risk, profitability, and long term earnings power feed into valuation.Mise à jour du récit • Apr 22
BIOA B: Future Returns Will Depend On High NLRP3 Execution Risk
Analysts have kept their SEK 240.0 price target for BioArctic unchanged, explaining the steady view by slightly adjusting discount rate, revenue growth, profit margin and future P/E assumptions, while balancing higher perceived risk with ongoing optimism around the broader NLRP3 and cardiovascular opportunity highlighted in recent peer research. Analyst Commentary Research coverage around NLRP3-targeted therapies has been active, with several firms updating their views and price targets on peers such as BioAge Labs.Mise à jour du récit • Apr 08
BIOA B: NLRP3 Opportunity And Alzheimer’s Data Will Shape Balanced Outlook
The analyst fair value estimate for BioArctic has shifted from SEK 294.60 to SEK 303.80, with analysts pointing to more constructive views on the NLRP3 opportunity set and comparisons to bullish Street research on peers as key drivers behind the updated target assumptions. Analyst Commentary Bullish analysts are drawing parallels between BioArctic's NLRP3 exposure and Street enthusiasm around peers such as BioAge Labs, where recent research has highlighted NLRP3 programs and adjacent cardiovascular and ophthalmology opportunities as a key value driver.Mise à jour du récit • Mar 25
BIOA B: Future Earnings Will Depend On High China Access Risk
Analysts have nudged their fair value estimate for BioArctic to SEK240 from SEK236. This reflects updated assumptions around revenue contraction, profitability and a higher future P/E multiple, while keeping the discount rate broadly similar.Mise à jour du récit • Mar 10
BIOA B: China Alzheimer’s Access And Delivery Shift Will Drive Future Upside
Analysts are keeping their SEK 367.0 price target for BioArctic broadly unchanged, with only modest tweaks to underlying assumptions. They highlight parallels with recent bullish Street research on early stage biotech names that are seeing renewed interest around differentiated clinical assets.Mise à jour du récit • Feb 24
BIOA B: Peer Re-Rating And China Alzheimer’s Momentum Will Reframe Upside
Analysts have raised their BioArctic fair value estimate from SEK353 to SEK367 as they factor in updated views on revenue growth, margins, discount rate and a higher future P/E assumption aligned with recent bullish Street research on comparable biotech names. Analyst Commentary Recent Street research on comparable biotech names has turned more optimistic, with bullish analysts revisiting their models and price targets in light of updated clinical views and perceived market potential.Mise à jour du récit • Feb 09
BIOA B: Future Earnings Will Depend On Risky China Insurance Access
Analysts have raised their fair value estimate for BioArctic from SEK 230 to SEK 236, citing updated assumptions regarding discount rates, revenue growth, profit margins and a slightly higher future P/E multiple. Analyst Commentary Recent analyst work on comparable neurology and biotech names highlights how sensitive valuations can be to small shifts in assumptions around discount rates, revenue build, profitability and terminal P/E multiples.Mise à jour du récit • Jan 25
BIOA B: Future Earnings Will Rely On Risky China Alzheimer Access
Analysts now keep their price target for BioArctic at SEK 230.00, with small adjustments to the discount rate, revenue growth assumptions and future P/E outlook. This reflects only minor changes to their overall view of the company’s risk and profitability profile.Mise à jour du récit • Jan 09
BIOA B: Future Earnings Will Depend On Risky Alzheimer Access Rollout
Analysts have maintained their fair value estimate for BioArctic at SEK 230.00. They have, however, adjusted assumptions related to the discount rate, revenue trends, profit margins, and future P/E to reflect updated views on the company’s risk profile and earnings potential.Mise à jour du récit • Dec 26
BIOA B Future Long Term Margin Upside Will Not Offset Demand Risks
Analysts have modestly raised their price target on BioArctic to SEK 230 (from SEK 230 previously), reflecting slightly lower perceived risk and a substantially improved long term profit margin outlook, despite marginally weaker revenue growth assumptions and a lower projected future P/E multiple. What's in the News Leqembi, developed by BioArctic and Eisai, has been included in China’s new Commercial Insurance Innovative Drug List.Mise à jour du récit • Dec 12
BIOA B: Future Revenue Weakness Will Outweigh Expanding Alzheimer’s Market Approval
Analysts have reduced their price target on BioArctic from SEK 280 to SEK 230. This reflects a more cautious outlook on future revenue growth despite improved profitability expectations and a slightly higher discount rate.Article d’analyse • Nov 16
BioArctic AB (publ) (STO:BIOA B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a pretty great week for BioArctic AB (publ) ( STO:BIOA B ) shareholders, with its shares surging 12% to kr295...Mise à jour du récit • Sep 17
Overhyped Valuations Will Falter Amid Healthcare Headwinds
Despite a significant improvement in BioArctic's net profit margin and a sharp decline in its future P/E multiple, the consensus analyst price target has been revised downward to SEK294.60. What's in the News FDA approved the Biologics License Application for weekly subcutaneous maintenance dosing of lecanemab (LEQEMBI IQLIK) for early Alzheimer's disease; U.S. launch set for October 6, 2025.Mise à jour du récit • Sep 02
Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration Care
BioArctic's consensus price target has been reduced to SEK280.50, primarily due to sharply lower revenue growth expectations and a significant drop in the projected future P/E multiple. What's in the News BioArctic entered an option, collaboration, and license agreement with Novartis Pharma involving its proprietary BrainTransporter technology for a potential neurodegeneration treatment, receiving USD 30 million upfront, with up to USD 772 million in potential milestone payments and tiered royalties.Article d’analyse • Aug 14
Revenues Not Telling The Story For BioArctic AB (publ) (STO:BIOA B) After Shares Rise 26%
OM:BIOA B 1 Year Share Price vs Fair Value Explore BioArctic's Fair Values from the Community and select yours Despite...Nouveau récit • Jun 01
Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration Care
Regulatory approvals and upcoming diagnostics are set to accelerate Leqembi adoption, expanding access and recurring royalty revenues from an underserved and growing patient base.Article d’analyse • May 29
BioArctic's (STO:BIOA B) Solid Profits Have Weak Fundamentals
BioArctic AB (publ)'s ( STO:BIOA B ) robust earnings report didn't manage to move the market for its stock. Our...Article d’analyse • May 16
Here's Why BioArctic AB (publ)'s (STO:BIOA B) CEO Compensation Is The Least Of Shareholders Concerns
Key Insights BioArctic will host its Annual General Meeting on 22nd of May CEO Gunilla Osswald's total compensation...Article d’analyse • Feb 19
Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)
Shareholders in BioArctic AB (publ) ( STO:BIOA B ) may be thrilled to learn that the analysts have just delivered a...Article d’analyse • Feb 18
Earnings Beat: BioArctic AB (publ) (STO:BIOA B) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
It's been a good week for BioArctic AB (publ) ( STO:BIOA B ) shareholders, because the company has just released its...Article d’analyse • Jan 31
Analysts Just Published A Bright New Outlook For BioArctic AB (publ)'s (STO:BIOA B)
Shareholders in BioArctic AB (publ) ( STO:BIOA B ) may be thrilled to learn that the analysts have just delivered a...Article d’analyse • Nov 27
Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)
Celebrations may be in order for BioArctic AB (publ) ( STO:BIOA B ) shareholders, with the analysts delivering a...Article d’analyse • Sep 01
BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
A week ago, BioArctic AB (publ) ( STO:BIOA B ) came out with a strong set of quarterly numbers that could potentially...Article d’analyse • Aug 15
Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024
The analysts covering BioArctic AB (publ) ( STO:BIOA B ) delivered a dose of negativity to shareholders today, by...Stabilité et croissance des paiements
Récupération des données sur les dividendes
Dividende stable: BIOA B ne verse pas de dividende notable pour le marché Swedish, il n'est donc pas nécessaire de vérifier si les paiements sont stables.
Dividende croissant: BIOA B ne verse pas de dividende notable pour le marché Swedish, il n'est donc pas nécessaire de vérifier si les paiements augmentent.
Rendement des dividendes par rapport au marché
| BioArctic Rendement des dividendes par rapport au marché |
|---|
| Segment | Rendement du dividende |
|---|---|
| Entreprise (BIOA B) | 0.6% |
| 25% du marché (SE) | 1.7% |
| 25% du marché (SE) | 4.2% |
| Moyenne du secteur (Biotechs) | 2.2% |
| Analyste prévisionnel (BIOA B) (jusqu'à 3 ans) | 0% |
Dividende notable: Le dividende de BIOA B ( 0.61% ) n'est pas notable par rapport aux 25 % des payeurs de dividendes les plus faibles du marché Swedish ( 1.72% ).
Dividende élevé: Le dividende de BIOA B ( 0.61% ) est faible par rapport aux 25 % des premiers payeurs de dividendes du marché Swedish ( 4.24% ).
Bénéfice distribué aux actionnaires
Couverture des revenus: BIOA B ne verse pas de dividende notable pour le marché Swedish.
Paiement en espèces aux actionnaires
Couverture des flux de trésorerie: BIOA B ne verse pas de dividende notable pour le marché Swedish.
Découvrir des entreprises qui versent des dividendes élevés
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/13 18:50 |
| Cours de l'action en fin de journée | 2026/08/13 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
BioArctic AB (publ) est couverte par 5 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |
| Viktor Sundberg | Nordea Markets |